<DOC>
	<DOC>NCT00401479</DOC>
	<brief_summary>This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.</brief_summary>
	<brief_title>A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Solabegron</mesh_term>
	<mesh_term>Adrenergic Agonists</mesh_term>
	<criteria>Subjects with no evidence of current or past history suggestive of gastrointestinal disease or disorder or medical illness that could compromise interpretation of the study. no clinically significant laboratory results collected at the screening visit men: body weight greater than or equal to 50kg (110 lbs) women: body weight greater than or equal to 45kg (100 lbs) BMI between 18.5 35 kg/m2 Females who are nursing or pregnant. history of inflammatory bowel disease history of gastric ulcers within 12 months of signing the informed consent form tobacco users</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>GW427353</keyword>
	<keyword>b3-Adrenergic Receptor Agonist</keyword>
	<keyword>Irritable Bowel Syndrome (IBS)</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tolerability</keyword>
	<keyword>gastrointestinal transit</keyword>
</DOC>